PortfoliosLab logo
BEAM vs. PRME
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between BEAM and PRME is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

BEAM vs. PRME - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Beam Therapeutics Inc. (BEAM) and Prime Medicine Inc. Common Stock (PRME). The values are adjusted to include any dividend payments, if applicable.

-100.00%-80.00%-60.00%-40.00%-20.00%December2025FebruaryMarchAprilMay
-60.30%
-91.41%
BEAM
PRME

Key characteristics

Sharpe Ratio

BEAM:

-0.31

PRME:

-0.80

Sortino Ratio

BEAM:

0.04

PRME:

-1.47

Omega Ratio

BEAM:

1.00

PRME:

0.84

Calmar Ratio

BEAM:

-0.26

PRME:

-0.80

Martin Ratio

BEAM:

-0.89

PRME:

-1.34

Ulcer Index

BEAM:

25.41%

PRME:

56.27%

Daily Std Dev

BEAM:

74.60%

PRME:

93.92%

Max Drawdown

BEAM:

-89.12%

PRME:

-94.55%

Current Drawdown

BEAM:

-86.97%

PRME:

-93.75%

Fundamentals

Market Cap

BEAM:

$1.99B

PRME:

$220.35M

EPS

BEAM:

-$4.58

PRME:

-$1.65

PS Ratio

BEAM:

31.38

PRME:

73.87

PB Ratio

BEAM:

2.72

PRME:

1.44

Total Revenue (TTM)

BEAM:

$63.58M

PRME:

$40.17M

Gross Profit (TTM)

BEAM:

$39.61M

PRME:

$38.45M

EBITDA (TTM)

BEAM:

-$285.27M

PRME:

-$149.31M

Returns By Period

In the year-to-date period, BEAM achieves a -29.80% return, which is significantly higher than PRME's -54.79% return.


BEAM

YTD

-29.80%

1M

6.35%

6M

-35.66%

1Y

-22.76%

5Y*

0.61%

10Y*

N/A

PRME

YTD

-54.79%

1M

14.78%

6M

-67.80%

1Y

-75.37%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

BEAM vs. PRME — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BEAM
The Risk-Adjusted Performance Rank of BEAM is 3636
Overall Rank
The Sharpe Ratio Rank of BEAM is 3535
Sharpe Ratio Rank
The Sortino Ratio Rank of BEAM is 3838
Sortino Ratio Rank
The Omega Ratio Rank of BEAM is 3838
Omega Ratio Rank
The Calmar Ratio Rank of BEAM is 3636
Calmar Ratio Rank
The Martin Ratio Rank of BEAM is 3131
Martin Ratio Rank

PRME
The Risk-Adjusted Performance Rank of PRME is 99
Overall Rank
The Sharpe Ratio Rank of PRME is 1010
Sharpe Ratio Rank
The Sortino Ratio Rank of PRME is 66
Sortino Ratio Rank
The Omega Ratio Rank of PRME is 1010
Omega Ratio Rank
The Calmar Ratio Rank of PRME is 55
Calmar Ratio Rank
The Martin Ratio Rank of PRME is 1313
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

BEAM vs. PRME - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Beam Therapeutics Inc. (BEAM) and Prime Medicine Inc. Common Stock (PRME). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current BEAM Sharpe Ratio is -0.31, which is higher than the PRME Sharpe Ratio of -0.80. The chart below compares the historical Sharpe Ratios of BEAM and PRME, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.50December2025FebruaryMarchAprilMay
-0.31
-0.82
BEAM
PRME

Dividends

BEAM vs. PRME - Dividend Comparison

Neither BEAM nor PRME has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

BEAM vs. PRME - Drawdown Comparison

The maximum BEAM drawdown since its inception was -89.12%, smaller than the maximum PRME drawdown of -94.55%. Use the drawdown chart below to compare losses from any high point for BEAM and PRME. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%December2025FebruaryMarchAprilMay
-65.82%
-93.75%
BEAM
PRME

Volatility

BEAM vs. PRME - Volatility Comparison

The current volatility for Beam Therapeutics Inc. (BEAM) is 30.42%, while Prime Medicine Inc. Common Stock (PRME) has a volatility of 37.06%. This indicates that BEAM experiences smaller price fluctuations and is considered to be less risky than PRME based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


15.00%20.00%25.00%30.00%35.00%40.00%December2025FebruaryMarchAprilMay
30.42%
37.06%
BEAM
PRME

Financials

BEAM vs. PRME - Financials Comparison

This section allows you to compare key financial metrics between Beam Therapeutics Inc. and Prime Medicine Inc. Common Stock. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M350.00M20212022202320242025
7.47M
2.18M
(BEAM) Total Revenue
(PRME) Total Revenue
Values in USD except per share items